|
Volumn 32, Issue 10, 2014, Pages 980-982
|
Development of the clinical next-generation sequencing industry in a shifting policy climate: To the editor
|
Author keywords
[No Author keywords available]
|
Indexed keywords
BIOINFORMATICS;
BLUE CROSS BLUE SHIELD;
CANCER DIAGNOSIS;
CLIMATE CHANGE;
CLINICAL LABORATORY;
CLINICAL PRACTICE;
COMMERCIAL PHENOMENA;
COMPUTER PROGRAM;
DIAGNOSTIC VALUE;
DRUG ADMINISTRATION;
FOOD;
GENOMICS;
GOLD STANDARD;
HEALTH CARE POLICY;
HEALTH CARE SYSTEM;
HUMAN;
INFORMATION PROCESSING;
LABORATORY TEST;
LAW;
LETTER;
MANUFACTURING INDUSTRY;
MEDICAL DEVICE;
MEDICAL TECHNOLOGY;
NEXT GENERATION SEQUENCING;
PATENT;
PRACTICE GUIDELINE;
PRIORITY JOURNAL;
RARE DISEASE;
REIMBURSEMENT;
BIOTECHNOLOGY;
HIGH THROUGHPUT SEQUENCING;
LEGISLATION AND JURISPRUDENCE;
ORGANIZATION AND MANAGEMENT;
TRENDS;
BIOTECHNOLOGY;
GENOMICS;
HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING;
HUMANS;
|
EID: 84924298892
PISSN: 10870156
EISSN: 15461696
Source Type: Journal
DOI: 10.1038/nbt.3030 Document Type: Letter |
Times cited : (22)
|
References (12)
|